Audentes Therapeutics (BOLD) Given News Sentiment Rating of 0.04
Media coverage about Audentes Therapeutics (NASDAQ:BOLD) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Audentes Therapeutics earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.092506232647 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern’s rankings:
- Russian Federation and China agree sanctions against North Korea useless (famososartistas.com)
- Audentes Therapeutics, Inc. (BOLD) Major Shareholder Sells $111,750.00 in Stock (americanbankingnews.com)
- Audentes Therapeutics, Inc. (BOLD) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- -$0.82 Earnings Per Share Expected for Audentes Therapeutics, Inc. (BOLD) This Quarter (americanbankingnews.com)
Audentes Therapeutics (NASDAQ BOLD) opened at 24.10 on Tuesday. The company’s market capitalization is $669.59 million. The stock has a 50 day moving average of $20.22 and a 200 day moving average of $17.37. Audentes Therapeutics has a 12-month low of $13.13 and a 12-month high of $24.49.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.10. On average, equities research analysts predict that Audentes Therapeutics will post ($3.53) EPS for the current year.
BOLD has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Monday, July 17th. Wedbush restated an “ourperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research report on Monday, May 15th. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, July 20th. Finally, Evercore ISI initiated coverage on shares of Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Audentes Therapeutics currently has an average rating of “Hold” and a consensus price target of $22.40.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 2,850 shares of the firm’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $20.00, for a total value of $57,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew R. Patterson sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total transaction of $300,000.00. The disclosure for this sale can be found here. Insiders sold a total of 55,850 shares of company stock valued at $1,136,970 in the last 90 days. Corporate insiders own 47.30% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Stock Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related stocks with our FREE daily email newsletter.